LPCN · NASDAQ
Lipocine (LPCN) Stock Price & Fundamentals
Lipocine (LPCN) closed at $733.14 on Oct 9, 2026, down 0.82% from the previous close of $739.21.
Share price, past year
1Y +10.77%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $733.14 |
| Sep 30, 2026 | $717.99 |
| Aug 31, 2026 | $673.92 |
| Jul 31, 2026 | $624.31 |
| Jun 30, 2026 | $608.08 |
| May 29, 2026 | $613.18 |
| Apr 30, 2026 | $610.74 |
| Mar 31, 2026 | $609.10 |
| Feb 27, 2026 | $615.59 |
| Jan 30, 2026 | $628.20 |
| Dec 31, 2025 | $631.97 |
| Nov 28, 2025 | $612.95 |
| Oct 31, 2025 | $695.43 |
Key statistics
- Market cap
- $6.04B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.79
- Revenue (TTM)
- $1.57M
- Net income (TTM)
- −$11.85M
- Shares outstanding
- 8.2M
- Dividend yield
- —
- 52-week range
- $600.80 – $739.21
Lipocine's market cap is $6.04B, based on a share price of $733.14 and 8.2M shares outstanding as of Jun 30, 2026.
Financials
Lipocine reported revenue of $1.98M for fiscal 2025, down 82.35% from fiscal 2024.
Lipocine reported a net loss of $9.63M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $1.98M | −82.4% | −$9.63M | −487.1% | −$1.69 | — |
| FY2024ended Dec 31, 2024 | $11.20M | +492.8% | $8.35K | 0.1% | — | −$1.31M |
| FY2023ended Dec 31, 2023 | −$2.85M | −670.2% | −$16.35M | 573.6% | −$3.14 | −$11.88M |
| FY2022ended Dec 31, 2022 | $500.00K | −96.9% | −$10.76M | −2,151.7% | −$2.15 | −$12.10M |
| FY2021ended Dec 31, 2021 | $16.14M | — | −$634.40K | −3.9% | −$0.01 | −$4.42M |
| FY2020ended Dec 31, 2020 | $0.00 | −100.0% | −$20.96M | — | −$0.38 | — |
| FY2019ended Dec 31, 2019 | $164.99K | −61.5% | −$13.01M | −7,883.7% | −$0.50 | — |
| FY2018ended Dec 31, 2018 | $428.03K | — | −$11.66M | −2,724.1% | −$0.55 | −$12.08M |
| FY2017ended Dec 31, 2017 | $0.00 | — | −$20.98M | — | −$1.05 | −$16.70M |
| FY2016ended Dec 31, 2016 | $0.00 | — | −$18.97M | — | −$1.04 | −$18.34M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $190.10K | −$2.62M | −$0.32 |
| Q1 FY2026ended Mar 31, 2026 | $119.40K | −$3.67M | −$0.54 |
| Q4 FY2025ended Dec 31, 2025 | $1.15M | −$2.37M | −$0.34 |
| Q3 FY2025ended Sep 30, 2025 | $114.57K | −$3.19M | −$0.59 |
| Q2 FY2025ended Jun 30, 2025 | $622.85K | −$2.21M | −$0.41 |
| Q1 FY2025ended Mar 31, 2025 | $93.86K | −$1.86M | −$0.35 |
| Q2 FY2024ended Jun 30, 2024 | $89.57K | — | −$0.56 |
| Q1 FY2024ended Mar 31, 2024 | $7.62M | — | — |
Company profile
- Name
- Lipocine Inc.
- Ticker
- LPCN
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 675 Arapeen Drive, Suite 202, Salt Lake City, X1 84108
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001535955
Recent SEC filings
- Oct 7, 2026
- Sep 16, 2026
- Sep 14, 2026
- Sep 11, 2026
- Sep 10, 2026
- Aug 4, 2026
- Aug 4, 2026
- Aug 3, 2026
Frequently asked questions
What is Lipocine's stock price?
Lipocine (LPCN) closed at $733.14 on Oct 9, 2026, down 0.82% from the previous close of $739.21.
What is Lipocine's market cap?
Lipocine's market cap is $6.04B, based on a share price of $733.14 and 8.2M shares outstanding as of Jun 30, 2026.
How much revenue does Lipocine make?
Lipocine reported revenue of $1.98M for fiscal 2025, down 82.35% from fiscal 2024.
Does Lipocine pay a dividend?
Lipocine's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Lipocine Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures